IN2012DN02210A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02210A
IN2012DN02210A IN2210DEN2012A IN2012DN02210A IN 2012DN02210 A IN2012DN02210 A IN 2012DN02210A IN 2210DEN2012 A IN2210DEN2012 A IN 2210DEN2012A IN 2012DN02210 A IN2012DN02210 A IN 2012DN02210A
Authority
IN
India
Prior art keywords
patient
methods
neurotoxin
prolongation
presented
Prior art date
Application number
Inventor
M Gaxiola Gustavo
E Aguilar Ivan
P Paz Gilberto
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2012DN02210A publication Critical patent/IN2012DN02210A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided.
IN2210DEN2012 2009-08-26 2010-08-10 IN2012DN02210A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/548,073 US8147848B2 (en) 2009-08-26 2009-08-26 Method for treating premature ejaculation with a botulinum neurotoxin
PCT/US2010/044959 WO2011028371A1 (en) 2009-08-26 2010-08-10 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin

Publications (1)

Publication Number Publication Date
IN2012DN02210A true IN2012DN02210A (en) 2015-08-21

Family

ID=43127150

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2210DEN2012 IN2012DN02210A (en) 2009-08-26 2010-08-10

Country Status (19)

Country Link
US (8) US8147848B2 (en)
EP (2) EP2708239B1 (en)
JP (2) JP5766699B2 (en)
KR (1) KR101612988B1 (en)
CN (2) CN103816530B (en)
AU (2) AU2010289969B2 (en)
BR (1) BR112012004246A2 (en)
CA (1) CA2772372C (en)
CY (1) CY1114792T1 (en)
DK (2) DK2470202T3 (en)
ES (2) ES2564677T3 (en)
HK (2) HK1171658A1 (en)
IN (1) IN2012DN02210A (en)
MX (2) MX349947B (en)
PL (1) PL2470202T3 (en)
PT (1) PT2470202E (en)
RU (1) RU2568844C2 (en)
SI (1) SI2470202T1 (en)
WO (1) WO2011028371A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US20120251518A1 (en) * 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20130066148A1 (en) * 2011-09-12 2013-03-14 Kang Seon Cho Method of augmenting glans
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
AU2013246882B2 (en) 2012-04-13 2017-10-19 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (II)
US9764010B2 (en) 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin
SG11201701619TA (en) * 2014-09-02 2017-03-30 American Silver Llc Botulinum toxin and colloidal silver particles
RU2565104C1 (en) * 2014-10-24 2015-10-20 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Method of treating premature ejaculation
CN110996979A (en) * 2017-05-18 2020-04-10 雷文斯治疗公司 Method for treating cervical dystonia
WO2018220232A1 (en) * 2017-06-02 2018-12-06 Universite De Versailles-St Quentin En Yvelines Pharmaceutical combination product comprising botulinum toxin for the treatment of erectile dysfunction

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5427291A (en) 1993-09-21 1995-06-27 Smith; David S. Ski carrier and method employing same
AU688452B2 (en) 1993-12-28 1998-03-12 Allergan, Inc. Botulinum toxins for treating various disorders and associated pain
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CN1123680A (en) * 1994-11-18 1996-06-05 吕建京 Effective health-care product for deficiency of the kidney, spleen and lung and its production
ES2385130T3 (en) 1997-07-15 2012-07-18 The Regents Of The University Of Colorado, A Body Corporate Use of neurotoxin therapy for the treatment of urological diseases and related diseases
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
CN1146866C (en) * 1998-11-17 2004-04-21 阿尔卑斯电气株式会社 Crown forming method of flying head and its crown forming device
FR2793689B1 (en) 1999-05-19 2001-08-24 Pf Medicament TRANSDERMAL DEVICE FOR THE ADMINISTRATION OF TESTOSTERONE OR A DERIVATIVE THEREOF
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
RU2180591C2 (en) * 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Agent for treatment of men with sexual disorders
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
WO2002074241A2 (en) 2001-03-16 2002-09-26 Dmi Biosciences Inc. Method of delaying ejaculation
EP1373203A1 (en) 2001-03-29 2004-01-02 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
ATE406900T1 (en) * 2002-01-25 2008-09-15 Modular Properties Ltd METHODS AND COMPOSITIONS FOR TREATING MALE ERECTIVE DISORDER
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
TW200418838A (en) 2002-09-18 2004-10-01 Bristol Myers Squibb Co Compounds for the treatment of premature ejaculation
US20070264373A1 (en) * 2004-01-26 2007-11-15 Ian Carroll Toxin Induced Sympathectomy
US20060100584A1 (en) 2004-08-10 2006-05-11 Orest Olejnik Needleless microprotrusion elastoplast system
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
CN1682810A (en) * 2005-02-22 2005-10-19 黄资源 Prostate external application powder for treating prostatic diseases
BRPI0608249A2 (en) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulation, method for topical application and kit for transdermal botulinum toxin delivery
JP4944896B2 (en) 2005-11-17 2012-06-06 ルバンス セラピュティックス インク． Compositions and methods for topical application and transdermal delivery of botulinum toxin comprising reduced non-toxin proteins
US7445783B2 (en) 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
EP2494958A1 (en) 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
US20090005319A1 (en) * 2007-07-01 2009-01-01 Barone Jr Frank V Topical compositions for delaying ejaculation and methods of using the same
US20090093547A1 (en) * 2007-10-09 2009-04-09 Sciele Pharma, Inc. Compositions and Methods for Treating Premature Ejaculation
CN101918021A (en) 2007-10-23 2010-12-15 阿勒根公司 Methods of treating urogenital-neurological disorders using modified clostridial toxins
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US9049616B2 (en) 2012-03-29 2015-06-02 Broadcom Corporation Session recovery after network coordinator or AP restart for single user, multiple user, multiple access, and/or MIMO wireless communications
US9764010B2 (en) 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin

Also Published As

Publication number Publication date
ES2446969T3 (en) 2014-03-11
PL2470202T3 (en) 2014-05-30
EP2708239A1 (en) 2014-03-19
EP2470202A1 (en) 2012-07-04
US20140140981A1 (en) 2014-05-22
JP2015163654A (en) 2015-09-10
HK1194292A1 (en) 2014-10-17
WO2011028371A1 (en) 2011-03-10
HK1171658A1 (en) 2013-04-05
US10420823B2 (en) 2019-09-24
JP2013503165A (en) 2013-01-31
US20130059789A1 (en) 2013-03-07
ES2564677T3 (en) 2016-03-28
DK2708239T3 (en) 2016-03-14
EP2470202B1 (en) 2013-12-18
JP5766699B2 (en) 2015-08-19
US20170020997A1 (en) 2017-01-26
AU2015213381A1 (en) 2015-09-03
CA2772372A1 (en) 2011-03-10
SI2470202T1 (en) 2014-02-28
AU2010289969A1 (en) 2012-03-22
RU2012110324A (en) 2013-10-10
US20110052636A1 (en) 2011-03-03
EP2708239B1 (en) 2015-12-09
MX2012002378A (en) 2012-06-28
CN102802663B (en) 2014-03-19
KR20120103760A (en) 2012-09-19
US20180185460A1 (en) 2018-07-05
US20150064167A1 (en) 2015-03-05
US9907841B2 (en) 2018-03-06
CN103816530A (en) 2014-05-28
AU2015213381B2 (en) 2017-05-25
US9186395B2 (en) 2015-11-17
US20120148563A1 (en) 2012-06-14
US8329193B2 (en) 2012-12-11
PT2470202E (en) 2014-02-24
CN102802663A (en) 2012-11-28
US8147848B2 (en) 2012-04-03
MX349947B (en) 2017-08-22
US8916177B2 (en) 2014-12-23
US9457069B2 (en) 2016-10-04
RU2568844C2 (en) 2015-11-20
AU2010289969B2 (en) 2015-05-14
CA2772372C (en) 2016-07-12
US8617570B2 (en) 2013-12-31
US20160067319A1 (en) 2016-03-10
KR101612988B1 (en) 2016-04-15
DK2470202T3 (en) 2014-01-27
BR112012004246A2 (en) 2016-04-05
JP6078108B2 (en) 2017-02-08
CY1114792T1 (en) 2016-12-14
CN103816530B (en) 2016-12-07

Similar Documents

Publication Publication Date Title
IN2012DN02210A (en)
MX2015005797A (en) Production of recombinant vaccine in e. coli by enzymatic conjugation.
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
MX364229B (en) COMPOSITIONS and METHODS FOR TREATING CARDIOVASCULAR DISEASES.
WO2012047733A3 (en) Treatment of acne by conditioned media
MX359854B (en) Anti-cxcr3 antibodies.
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
MX2011010930A (en) Modulation of inflammatory responses by factor xi.
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
MX343931B (en) Treatment of amyotrophic lateral sclerosis using umbilical derived cells.
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
GB2523696A (en) Methods of differentiating stem cells by modulating miR-124
PH12016500136A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
EP2579863A4 (en) Compounds for treatment of bovine mastitis
MX336359B (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound.
MX364528B (en) Withanolides useful for the treatment of neurodegenerative diseases.
UA103197C2 (en) Use of nifurtimox for the treatment of diseases caused by trichomonadida
MX2012000203A (en) Methods of using corticotropin-releasing factor for the treatment of cancer.
AU2012240388A8 (en) Treatment regimens
WO2012112862A3 (en) Treating mycobacterial infection with cu+/++ boosting therapeutics
MD20140001A2 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
MX359171B (en) Treatment of type i and type ii diabetes.
UA44395U (en) Use of tiocetam as a diuretic drug with mild emictory action in a complex treatment